Introduction
Immune cells have been acknowledged as causal mediators of atherosclerosis, eliciting arterial wall inflammation. 1 One of the processes contributing to arterial wall inflammation is the continuous influx of novel leucocytes. 2 Early experimental evidence emphasized the particular importance of monocytes in aggravating arterial wall inflammation leading to accelerated atherosclerosis in murine models. 3 More recently we substantiated these findings in humans, showing the importance of influx of peripheral blood mononuclear cells (PBMCs) in atherosclerotic lesions, where newly transmigrated PBMCs correlate with the overall inflammatory status of these lesions. 2 Two pivotal steps facilitating recruitment are adhesion to the endothelial surface and subsequent transmigration of monocytes. These processes are initiated by chemokine receptors and adhesion molecules on monocytes interacting with their ligands expressed by endothelial cells. 4 Patients with cardiovascular disease (CVD) are characterized by increased arterial wall inflammation 5 and an increased number of circulating leucocytes with an activated phenotype. 6, 7 Although extensively investigated in animal studies, currently no data exists on the relation between monocyte activation patterns and arterial wall inflammation in humans.
We performed a post hoc analysis in 79 patients at increased risk of CVD in whom arterial wall 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake was quantified using positron emission tomography/computed tomography (PET/ CT) imaging, a validated method to measure arterial wall inflammation. 8 In the present study, we aimed to explore the relationship between activation patterns of circulating monocytes and arterial wall inflammation. We hypothesized that the expression levels of chemokine receptors (CCR2 and CCR5) and adhesion molecules (CD18, CD11b, CD11c) on circulating monocytes correlated with the extent of arterial wall inflammation. 9 
Methods
We performed a post hoc analysis of five studies, [10] [11] [12] [13] [14] collectively comprising 79 patients at increased risk of CVD. These five studies were performed at a single centre (Academic Medical Centre) between 2013 and 2016, using identical arterial wall imaging protocols and image analysis methods. Also in all studies, monocyte phenotype was characterized using flow cytometry for a predefined set of surface markers. Briefly, the studies included subjects over 50 years of age, with underlying diseases predisposing to CVD, namely patients with peripheral artery disease (PAD) (n = 32) with or without diabetes mellitus (DM) type II, chronic kidney disease (CKD) (n = 11), rheumatoid arthritis (RA) (n = 14), elevated levels of lipoprotein (a) (Lp(a)) (>500 mg/L) (n = 7), or elevated levels of remnant cholesterol (>0.7 mmol/L) (n = 15). Subjects were excluded if they experienced an acute cardiovascular event 6 months prior to study inclusion. Baseline data (age, gender, smoking status, blood pressure, and cholesterol levels) were extracted from the main studies. Hypertension is defined as a systolic blood pressure > _ 140 mmHg at baseline measurement or the use of anti-hypertensive medication. CRP and Lp(a) were assessed using immunoturbidimetry, 15, 16 lipid levels were measured via a colimetrical test using enzyme reactions (cholesterol esterase and oxidase), 17 while LDL cholesterol is calculated with the Friedewald formulae. 18 Leucocyte count and differentiation were determined using automated cell counters. Subjects lacking either 18 F-FDG PET/CT imaging or flow cytometry data were excluded. The studies were approved by the institutional review board of the Academic Medical Centre in Amsterdam, the Netherlands and conducted according to the principles of the declaration of Helsinki. Written informed consent was present for each participant.
18F-FDG PET/CT scan

18
F-FDG PET/CT scans were performed on a dedicated scanner (Philips, Best, the Netherlands). Patients were fasted for at least 6 h. A PET scan was performed 90 min after intravenous administration of 18 F-FDG (100 or 200 MBq). PET acquisition was combined with a low-dose (40 mAs), noncontrast enhanced CT for attenuation correction and anatomic coregistration (slice thickness 3 mm, 120 KvA). The images were obtained from the internal auditory meatus to the diaphragm, including three bed positions, resulting in images of both common carotid arteries and ascending aorta.
Images were analysed by experienced readers blinded for patient data, 5 using dedicated software (OsiriX, Geneva, Switzerland; http://www.osirixviewer.com). Arterial 18 F-FDG uptake was quantified using validated methods. 8 Briefly regions of interest (arterial and venous) are delineated on five subsequent slices of the co-registered transaxial images, for both the ascending aorta (five slices cranial, starting one slice cranial to the pulmonary arteries) and the carotid arteries (five slices caudal, starting one slice caudal to the carotid bifurcation). Average maximal standardized uptake values (SUV max: decay-corrected tissue concentration of FDG in kBq/mL, adjusted for the injected dose) in the five slices was divided by the average venous background activity (SUV mean ) in the superior caval vein or jugular vein to obtain the maximal target-to-background-ratio (TBR max ). 8 In line with previous reports, arterial wall inflammation is defined as the mean TBR max in the vessel with the highest FDG uptake. 5 
Flow cytometry
Red blood cells were lysed with red blood cell lysis buffer (Affymetrix, eBioscience, San Diego, USA; 700 lL plasma from the patient with 6.3 mL red blood lysis buffer) for 15 min; afterwards plasma was washed with 28 mL phosphate buffered saline (PBS) to stop the reaction. After centrifugation (387 g, 5 min, 4 C) and decantation of the supernatant, leucocytes remained.
First, the leucocytes were suspended in 200 lL PBS, next these leucocytes were incubated with fluorochrome labelled antibodies (per well: 25 lL leucocytes and 25 lL antibody; see Supplementary material online, Table S1 ) for 15 min (room temperature, dark). After incubation, the leucocytes were washed again with 140 lL PBS to stop the process. The cells were centrifuged (441 g, 3 min, 4 C). Thereafter, the supernatant was decanted and the cell pellet was suspended in 200 lL PBS. These cells were used for analysis.
Samples were analysed using BD FACS Canto II (Becton, Dickinson, Fanklin Lakes, NJ, USA). Per patient, 5000 monocyte events were acquired. Monocyte subsets (i.e. classical, intermediate, and non-classical monocytes) were classified according to HLA-DR, CD14, and CD16 expression (see Supplementary material online, Table S1 ). 19 The gating strategy is outlined in Figure 1A -D. Subsequently, the presence of chemokine receptors and vascular adhesion molecules on these monocytes was determined, i.e. CCR2, CCR5, CD11b, CD11c, and CD18. 9 Samples were analysed using FlowJo 
Statistical analysis
All data were analysed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). Data are presented as the mean ± standard deviation (SD) for normally distributed data, the median with interquartile range (IQR) for non-normally distributed data, or as a number (percentage) for categorical variables. Pearson correlation coefficients or Spearman Rho's for respectively normally distributed and non-normally distributed data were used to assess the correlation between TBR max and monocyte count, monocyte subsets and monocyte surface markers. Correlations between monocyte surface markers and TBR max were adjusted using a multivariate linear regression to correct for underlying disease, statin use, and traditional cardiovascular risk factors (gender, age, BMI, smoking, hypertension, LDL-c, and diabetes). The analysis for the total cohort is corrected for multiple testing using the Bonferroni method. 20 A multivariate linear regression test with backward analysis was performed to assess the contribution of traditional cardiovascular risk factors, statin use, and CRP to arterial wall inflammation (TBR max ) and to assess the effect of these risk factors on the expression of monocyte surface markers. Backward stepwise elimination (probability for removal P > 0.1) resulted in the final model. For this analysis, non-normally distributed data were converted to normally distributed data via a natural logarithm (LN). Differences in the distribution of monocytes subsets and CCR2 expression between the different groups 'underlying disease', as well as the difference between CCR2 expression on monocyte subsets, were assessed by a one-way ANOVA test and Kruskal-Wallis test for respectively normally and non-normally distributed data. Correction for outliers was applied using a Grubb's test with a P-value <0.05. 20 A two-sided P-value <0.05 was considered statistically significant. 
Results
Baseline cardiovascular risk factors and TBR metrics
We included 79 patients at increased risk of CVD. The baseline characteristics of these patients are listed in Table 1 . Patients were 61 ± 9 years old; 54% were male. Average BMI was 27 ± 4 kg/m 2 , mean systolic blood pressure 143 ± 22 mmHg, 32% had DM type II, and 41% used statins. Baseline characteristics per group are provided in Supplementary mate rial online, Table S2 . Medication use is displayed in more detail in the Supplementary material online (Table S3 ). Significant differences were observed in baseline characteristics reflecting the underlying diseases: patients with PAD and concomitant DM type II had higher BMI and a higher prevalence of hypertension. Patients with RA used diseasemodifying antirheumatic drugs (DMARDS) and/or anti-TNFa medication and were in clinical remission at the time of the measurements. 11 In all, 91% of the patients with CKD used anti-hypertensive medication. Furthermore, the inclusion of patients with high Lp(a) and remnant cholesterol (who are characterized by increased total cholesterol and triglyceride levels) resulted in significant differences in baseline lipid levels.
Patients with PAD, CKD, and elevated levels of remnant cholesterol had higher TBR max levels compared with patients with RA and elevated levels of Lp(a).
To account for potential confounding of these individual variables, we first assessed whether the different traditional cardiovascular risk factors correlated with the degree of arterial wall inflammation (TBR max ) in the entire cohort. Multivariate linear regression with backward analysis showed that only DM type II predicted arterial wall inflammation (standardized coefficient b = 0.264, P = 0.04). Other risk factors (gender, age, BMI, smoking, hypertension, and LDL-c), statin use, and CRP showed no significant correlation to arterial wall inflammation in the present cohort, as shown in Table 2 .
Correlation between monocyte activation patterns and TBR metrics Next, we aimed to assess the relationship between monocyte count or activation patterns and TBR max , overall we observed no correlation between total monocyte count and TBR max (r = 0.095, P = 0.409). Specific monocyte subset analysis also failed to show a correlation with TBR max [classical monocytes (CD14 þ CD16 -): r = 0.069, P = 0.568; inter-
Monocyte subset distribution differed between disease groups (Table 3) ; however, the correlation remained absent after correction for underlying disease (data not shown). To further investigate monocyte activation patterns in relation to arterial wall inflammation, we assessed the correlation between expression of surface markers on monocytes and TBR max . Upon assessment of 5 different surface markers we found that CCR2 expression correlated significantly with arterial wall inflammation (b = 0.429, P = 0.015, Figure 2A ). In line with current knowledge, 9 CCR2 is preferentially expressed on classical monocytes ( Figure 1E , P = 0.001). Concurrent with the difference in monocyte subsets between disease groups, we also found different CCR2 levels within the disease groups ( Table 3) , but after adjustment for potential confounders including the underlying disease, traditional cardiovascular risk factors and statin use the correlation between CCR2 and TBR max remained significant. Adjusted data are shown via a partial regression plot in the Supplementary material online ( Figure S1 ).
To further diverge disease specific contribution, as DM type II showed a significant correlation to TBR max in our cohort, we also assessed the correlation between CCR2 and TBR max separately in patients without DM type II (n = 53), but this did not affect the outcome (b = 0.451, adjusted P = 0.023) as shown in Figure 2B . As patients with RA used antiinflammatory therapies (DMARDS and/or anti-TNFa) and were in clinical remission, which might influence the TBR, we also evaluated the correlation between CCR2 and TBR max in patients without RA (n = 65). Again, this did not affect the outcome (b = 0.449, adjusted P = 0.005), as shown in Figure 2C . Other chemokine receptors and vascular adhesion molecules on monocytes (e.g. CCR5, CD18, CD11b, and CD11c) did not show a significant correlation with TBR max after correction for multiple testing, as shown in Table 4 . Finally, to further evaluate generalizability of our data, CCR2 levels in a cohort of apparently healthy subjects were assessed (due to ethical restrictions, arterial wall inflammation is not available in these subjects). We found that median CCR2 levels were not different from the whole cohort (P = 0.535), but lower than the subgroups with the highest TBR max (i.e. PAD, CKD and remnant) and comparable to patients with RA and elevated levels of Lp(a) ( Table 3) , who concurrently showed lower TBR max levels.
Traditional risk factors associated with the expression of CCR2 on monocytes
To explore the relative contribution of the different cardiovascular risk factors to the level of CCR2 expression on circulating monocytes, we Values are mean ± SD or median (IQR) for respectively normally and non-normally distributed data. P-value represents the difference in CCR2 expression and monocyte subset distribution between the groups 'underlying disease', assessed by the one-way ANOVA test for monocyte subset distribution and the Kruskal-Wallis test for non-normally distributed CCR2 expression. IQR, interquartile range; MFI, mean fluorescent intensity; SD, standard deviation.
Figure 1
Gating strategy for monocytes and their subtypes via flow cytometry and the expression of CCR2 on monocyte subsets. Flow cytometry on whole blood was performed to study monocyte subsets and specific surface expression markers. Leucocytes were separated using forward/sideward scatter (A). Following monocyte subsets were classified according CD14, CD16 (B), and HLA-DR (C) expression. We distinguish classical (CD14 þþCD16-), intermediate (CD14 þþCD16þ), and non-classical (CD14þCD16þ) monocytes (D used multiple linear regressions with backward analysis. Male gender, elevated blood pressure, and LDL-c showed a significant correlation with CCR2 after stepwise backward elimination, as shown in Table 5 .
Discussion
Here, we show that the activation pattern of circulating monocytes correlates to the degree of arterial wall inflammation. Specifically, expression of chemokine receptor CCR2 is associated with increased arterial wall inflammation. In contrast, no correlation was found between the expression of CCR5, CD11b, CD11c, and CD18 on monocytes and arterial wall inflammation, and there was no association with monocyte subsets or the absolute count. In line with previous studies, 21, 22 traditional risk factors for CVD did not correlate with arterial wall inflammation. Contrary, male gender, elevated blood pressure, and LDL-c showed a significant correlation with CCR2 expression.
Figure 2
The expression of CCR2 on monocytes is correlated with TBR max . Flow cytometry on whole blood was performed to differentiate monocyte subsets and to study the expression of chemokine receptors and vascular adhesion molecules on these monocytes. The mean of the maximal 18F-FDG uptake in five slices, represented as TBR max , displays arterial wall inflammation. In this figure, the correlation (using Spearman's Rho correlation coefficient) between CCR2 expression (represented as MFI, y-axis) and arterial wall inflammation (represented as TBR max , x-axis), is presented per group 'underlying disease' (A), unadjusted for traditional cardiovascular risk factors and statin use. Exclusion of patients with type II DM (B) or RA (C) did not affect outcome, shown per group. R, Spearman's Rho correlation coefficient. CCR2, C-C chemokine receptor 2; MFI, mean fluorescent intensity. Experimental evidence previously showed that CCR2 expression on circulating monocytes is an important contributing factor to atherogenesis in mice. 23, 24 In fact, CCR2 inhibition markedly reduced monocyte influx in the arterial wall, thereby reducing macrophage content in atherosclerotic plaques. 25 We recently reported that increased CCR2 expression on circulating monocytes coincided with an enhanced endothelial migration rate of monocytes in patients with familial hypercholesterolemia. 26 In the present study, we substantiate that monocyte CCR2 expression correlates with LDL-c concentration in a wider population at risk for CVD, independent of the underlying disease. Although complete data for a healthy control group is lacking, we observe that CCR2 levels in this group are comparable to the lowest CCR2 levels in the affected cohort, and in the present study, these subjects have TBR max levels comparable to thresholds set for apparently healthy subjects in a previous report. 5 Mechanistically, it was previously shown in vitro that elevated plasma LDL-c also lead to cholesterol accumulation in circulating monocytes, potentially upregulating CCR2 expression. 27 In support of a causal relation between LDL-c and CCR2 expression, selective reduction of LDL-c following proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition resulted in a marked decrease of CCR2 expression on monocytes. 26 Expression of CCR2 is however not only correlated with LDL-c. In patients with chronic inflammatory diseases, comprising CKD and RA, 11,13 the systemic inflammatory state was also associated with increased monocyte CCR2 expression, which decreased following treatment of the underlying disease activity. 28 Whether potent lowering of traditional risk factors for CVD is sufficient to reduce CCR2 expression on monocytes to levels observed in apparently healthy subjects remains to be investigated. The finding that CCR2, but not the classical monocyte subset, correlates to TBR max , even though CCR2 expression occurs predominantly on this subset, is in line with the notion that substantial heterogeneity in chemokine surface expression and employment exist within the three previously defined subsets, 1 and that searching for specific properties rather than broad divisions might identify selective targets to combat the inflammatory component in CVD. The aforementioned findings imply that strategies aimed at selectively reducing CCR2 activity may reduce monocyte transmigration as well as arterial wall inflammation. Interestingly, a Phase II clinical trial using MLN-1202, a humanized monoclonal antibody which inhibits binding of monocyte chemotactic protein-1 (MCP-1) to CCR2, has shown to markedly reduce CRP in patients at risk for CVD after 12 weeks of treatment. 29 CRP itself however is thought to be a marker, not a mediator in CVD, which is supported by Mendelian randomization studies. 30 In line with previous studies, 21 CRP showed no correlation to arterial wall inflammation in the present study. Unfortunately, no data on monocyte CCR2 expression on arterial wall inflammation upon MLN-1202 treatment are available. 31 In the current study, 18 FDG-PET/CT was used to assess arterial wall inflammation. Arterial wall inflammation has emerged as a promising surrogate marker for CVD risk. 32 Since inflammatory cells use more glucose than other cells in the arterial wall, 18 F-FDG PET/CT has been used to enable quantification of inflammatory activity in atherosclerotic plaques. 33 Previous studies demonstrated a clear relation between 18 F-FDG uptake and inflammatory activity in the arterial wall. 34,35 18 F-FDG uptake was shown to be associated with plaque macrophage content, as well as with CD68 gene expression, a marker of macrophages. 35, 36 Here, we show that also the expression of CCR2 on monocytes is associated with arterial wall inflammation and thus CVD risk.
Our study has several limitations. First, we included patients with a wide array of underlying diseases comprising both risk factors for CVD as well as known PAD. This might introduce heterogeneity in the correlation between different subgroups. Indeed, DM type II (32% of the total cohort) shows a significant correlation with TBR max . However, after adjustment for DM type II as well as for other underlying diseases and traditional CVD risk factors, the correlation between CCR2 and arterial wall inflammation was not attenuated. Furthermore, after exclusion of patients with RA, who use anti-inflammatory medication, the correlation remained. Moreover, patients in this cohort have relatively low levels of LDL-c (potentially partially due to a 42% statin use); in patients with higher LDL-c levels the correlation between the expression of CCR2 and arterial wall inflammation could be even more pronounced. Second, the relatively limited group size of 79 patients may have obscured our ability to detect other correlations between monocyte phenotypes and TBR max . Future studies using larger cohorts might unravel other monocyte markers being related to arterial wall inflammation. Also the lack of a control group with data on both arterial wall inflammation and monocyte phenotype limits generalization of our findings.
Thirdly, despite the fact that we didn't show a significant correlation for respectively the chemokine CCR5 and adhesion molecules CD11b, CD11c, and CD18 with arterial wall inflammation, the interplay between different chemokines and their receptors is complex: differential coexpression of the markers measured, as well as those that were not taken into account, are likely to contribute to pro-and antiinflammatory properties of monocytes (for instance CX3CR1, the fractalkine receptor, which is receiving increasing attention in CVD). 37 Due to the retrospective nature of this study, it is not possible to assess the relation between arterial wall inflammation and other chemokines and adhesion molecules at the present time.
In conclusion, here, we provide evidence that the expression of CCR2 on monocytes could be important for the degree of arterial wall inflammation, thereby mediating cardiovascular event risk.
Future studies about the relation between CCR2 and arterial wall inflammation are required to further elucidate the role of the expression of CCR2 on arterial wall inflammation. If this relation becomes more validated, inhibition of CCR2 expression by either lowering risk factors or by using a CCR2 antibody might be a promising future therapeutic target to further attenuate arterial wall inflammation and thus CVD risk.
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